| Citation: |
SUN Mengxiong, YANG Shuai, ZHI Xiongli, YUE Yanjun. Expression and significance of serum complements and blood lipid indexes in patients with coronary heart disease after atorvastatin treatment[J]. Journal of Clinical Medicine in Practice, 2022, 26(24): 71-75. DOI: 10.7619/jcmp.20222514
|
To observe the changes of complement C3, C4 and high-density lipoprotein cholesterol (HDL-C) levels in patients with coronary heart disease (CHD) after atorvastatin treatment and analyze the related factors affecting the poor prognosis of patients.
A total of 100 patients with CHD were selected as CHD group and randomly divided into atorvastatin group and control group, and another 100 healthy people in the same period were selected as healthy group. The levels of complement C3, C4, HDL-C, interleukin-6 (IL-6) and C reactive protein (CRP) were compared among three groups, and the efficiency of complement C3, C4 and HDL-C in diagnosing CHD was analyzed; the multivariate Logistic regression model was used to analyze the influencing factors of poor prognosis.
The levels of complement C3 and C4 in the CHD group were significantly higher than those in the healthy group, while the level of HDL-C was significantly lower than that in the healthy group (P < 0.05). The sensitivity and specificity of complement C3, C4 and HDL-C in the diagnosis of CHD were not lower than 80.00% and 75.00% respectively, and the area under the curve (AUC) was greater than 0.80. The total effective rate of the atorvastatin group was 86.00%, which was significantly higher than 68.00% of control group (P < 0.05). Levels of HDL-C at 1 month after treatment (T2) and 2 months after treatment (T3) in the atorvastatin group were significantly higher than that in the control group, while levels of IL-6 and CRP were significantly lower than those in the control group (P < 0.05). The incidence of poor prognosis in the atorvastatin group was 20.00% (10/50), which was significantly lower than 34.00% (17/50) in the control group (P < 0.05). Univariate analysis showed that the incidence of poor prognosis was significantly higher in severe patients in the atorvastatin group (P < 0.05). Multivariate Logistic regression model analysis showed that severe status of disease severity was a risk factor for poor prognosis of CHD patients after atorvastatin treatment (P < 0.001).
The levels of complement C3 and C4 in the CHD patients increase abnormally, while HDL-C level decreases abnormally; complement C3, C4 and HDL-C have high sensitivity and specificity in the diagnosis of CHD; atorvastatin treatment for CHD patients can improve the efficacy and HDL-C level, reduce the risks of inflammatory factors and poor prognosis, and the severity of the disease is an independent influencing factor for poor prognosis of CHD patients after atorvastatin treatment.
| [1] |
邓俊杰, 呼靖宣, 李兴华, 等. 小而密低密度脂蛋白胆固醇预测老年冠心病患者主要不良心血管事件的价值[J]. 实用临床医药杂志, 2022, 26(3): 34-38. doi: 10.7619/jcmp.20214401
|
| [2] |
贾娜, 何青. 老年人冠心病治疗的现状和临床策略[J]. 中华老年医学杂志, 2019, 38(10): 1175-1179. doi: 10.3760/cma.j.issn.0254-9026.2019.10.028
|
| [3] |
左继岩. 分析不同他汀类药物治疗早发冠心病急性心肌梗死患者临床效果[J]. 吉林医学, 2018, 39(3): 483-487. https://www.cnki.com.cn/Article/CJFDTOTAL-JLYX201803036.htm
|
| [4] |
张远生, 史丽. 瑞舒伐他汀与阿托伐他汀对冠心病伴高脂血症患者的临床研究[J]. 中国临床药理学杂志, 2019, 35(4): 315-318. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ201904001.htm
|
| [5] |
中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 稳定性冠心病基层诊疗指南(2020年)[J]. 中华全科医师杂志, 2021, 20(3): 265-273.
|
| [6] |
王鹏, 严妍, 于文君, 等. 阿托伐他汀与瑞舒伐他汀对冠心病患者的疗效与安全性对比观察[J]. 中国医院药学杂志, 2018, 38(2): 169-172, 202. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYZ201802014.htm
|
| [7] |
韦耀. 美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床疗效分析[J]. 实用临床医药杂志, 2017, 21(15): 183-184. doi: 10.7619/jcmp.201715062
|
| [8] |
栗程, 刘丹. 冠心病患者血清补体C3、C4及HDL-C水平分析[J]. 中华心脏与心律电子杂志, 2018, 6(2): 68-70. https://www.cnki.com.cn/Article/CJFDTOTAL-XZXL201802002.htm
|
| [9] |
RODNEY RODRIGUES DE ASSIS D, ALMEIDA OLIVEIRA A, LUIZ PORTO S, et al. 4-Chlorophenylthioacetone-derived thiosemicarbazones as potent antitrypanosomal drug candidates: investigations on the mode of action[J]. Bioorg Chem, 2021, 113: 105018.
|
| [10] |
ZINELLU A, MANGONI A A. Serum complement C3 and C4 and COVID-19 severity and mortality: a systematic review and meta-analysis with meta-regression[J]. Front Immunol, 2021, 12: 696085.
|
| [11] |
乔以凤, 杨艳, 周保成, 等. 冠心病患者血常规及血脂综合指标的临床意义[J]. 实用临床医药杂志, 2017, 21(21): 203-204. doi: 10.7619/jcmp.201721084
|
| [12] |
GUO L L, CHEN Y Q, LIN Q Z, et al. Non-HDL-C is more stable than LDL-C in assessing the percent attainment of non-fasting lipid for coronary heart disease patients[J]. Front Cardiovasc Med, 2021, 8: 649181.
|
| [13] |
周永峰, 党伟丽. 阿托伐他汀对冠心病患者经皮冠状动脉介入术后血管内皮功能及血脂的影响[J]. 实用临床医药杂志, 2020, 24(14): 100-102. doi: 10.7619/jcmp.202014027
|
| [14] |
KURL S, JAE S Y, VOUTILAINEN A, et al. The combined effect of blood pressure and C-reactive protein with the risk of mortality from coronary heart and cardiovascular diseases[J]. Nutr Metab Cardiovasc Dis, 2021, 31(7): 2051-2057.
|
| [15] |
LI H Y, SUN K, ZHAO R P, et al. Inflammatory biomarkers of coronary heart disease[J]. Front Biosci (Schol Ed), 2018, 10(1): 185-196.
|
| [16] |
李加林, 唐毓启, 胡志勇. 不同剂量阿托伐他汀治疗冠心病的疗效及对血清细胞因子和颈动脉粥样硬化斑块的影响[J]. 河北医药, 2017, 39(21): 3297-3299. https://www.cnki.com.cn/Article/CJFDTOTAL-HBYZ201721025.htm
|
| 1. |
刘彦. 阿托伐他汀联合曲美他嗪治疗冠心病的临床效果与药学机制分析. 智慧健康. 2023(22): 70-73 .
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: